References
Items 241 to 252 of 7892 total
- Precopio ML et al. (MAR 2003) Journal of immunology (Baltimore, Md. : 1950) 170 5 2590--8
Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection.
The generation and maintenance of virus-specific CD4(+) T cells in humans are not well understood. We used short in vitro stimulation assays followed by intracellular cytokine staining to characterize the timing, magnitude, and Ag specificity of CD4(+) T cells over the course of primary EBV infection. Lytic and latent protein-specific CD4(+) T cells were readily detected at presentation with acute infectious mononucleosis and declined rapidly thereafter. Responses to BZLF-1, BMLF-1, and Epstein-Barr nuclear Ag-3A were more commonly detected than responses to Epstein-Barr nuclear Ag-1. Concurrent analyses of BZLF-1-specific CD4(+) and CD8(+) T cells revealed differences in the expansion, specificity, and stability of CD4(+) and CD8(+) T cell-mediated responses over time. Peripheral blood EBV load directly correlated with the frequency of EBV-specific CD4(+) T cell responses at presentation and over time, suggesting that EBV-specific CD4(+) T cell responses are Ag-driven.Catalog #: Product Name: 15024 RosetteSepâ„¢ Human B Cell Enrichment Cocktail Catalog #: 15024 Product Name: RosetteSepâ„¢ Human B Cell Enrichment Cocktail Sakai R et al. (MAR 2003) Toxicological sciences : an official journal of the Society of Toxicology 72 1 84--91TCDD treatment eliminates the long-term reconstitution activity of hematopoietic stem cells.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an endocrine disrupting chemical (EDC), can cause carcinogenesis, immunosuppression, and teratogenesis, through a ligand-activated transcription factor, the aryl hydrocarbon receptor (AhR). Despite remarkable recent advances in stem cell biology, the influence of TCDD on hematopoietic stem cells (HSCs), which possess the ability to reconstitute long-term multilineage hematopoiesis, has not been well investigated. In this study we examined the influence of TCDD on HSCs enriched for CD34(-), c-kit(+), Sca-1(+), lineage negative (CD34-KSL) cells. The number of the CD34-KSL cells was found to be increased about four-fold upon a single oral administration of TCDD (40 micro g/kg body weight). Surprisingly, we found that these TCDD-treated cells almost lost long-term reconstitution activity. This defect was not present in AhR(-/-) mice. These findings suggest that modulation of AhR/ARNT system activity may have an effect on HSC function or survival.Catalog #: Product Name: 03434 MethoCultâ„¢ GF M3434 Catalog #: 03434 Product Name: MethoCultâ„¢ GF M3434 Ring DB et al. ( 2003) Diabetes 52 3 588--595Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
Insulin resistance plays a central role in the development of type 2 diabetes, but the precise defects in insulin action remain to be elucidated. Glycogen synthase kinase 3 (GSK-3) can negatively regulate several aspects of insulin signaling, and elevated levels of GSK-3 have been reported in skeletal muscle from diabetic rodents and humans. A limited amount of information is available regarding the utility of highly selective inhibitors of GSK-3 for the modification of insulin action under conditions of insulin resistance. In the present investigation, we describe novel substituted aminopyrimidine derivatives that inhibit human GSK-3 potently (K(i) textless 10 nmol/l) with at least 500-fold selectivity against 20 other protein kinases. These low molecular weight compounds activated glycogen synthase at approximately 100 nmol/l in cultured CHO cells transfected with the insulin receptor and in primary hepatocytes isolated from Sprague-Dawley rats, and at 500 nmol/l in isolated type 1 skeletal muscle of both lean Zucker and ZDF rats. It is interesting that these GSK-3 inhibitors enhanced insulin-stimulated glucose transport in type 1 skeletal muscle from the insulin-resistant ZDF rats but not from insulin-sensitive lean Zucker rats. Single oral or subcutaneous doses of the inhibitors (30-48 mg/kg) rapidly lowered blood glucose levels and improved glucose disposal after oral or intravenous glucose challenges in ZDF rats and db/db mice, without causing hypoglycemia or markedly elevating insulin. Collectively, our results suggest that these selective GSK-3 inhibitors may be useful as acute-acting therapeutics for the treatment of the insulin resistance of type 2 diabetes.Catalog #: Product Name: 72052 CHIR99021 73042 CHIR98014 Catalog #: 72052 Product Name: CHIR99021 Catalog #: 73042 Product Name: CHIR98014 Bruserud &O et al. (MAY 2003) Leukemia research 27 5 455--64In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines.
The aim of this study was to standardize in vitro culture conditions for human acute lymphoblastic leukemia (ALL) cells. The cells were cultured in medium containing 10% fetal calf serum (FCS) and in the four serum-free media X-vivo 10, X-vivo 15, X-vivo 20 and Stem Span. Native ALL blasts could proliferate in all four serum-free media, but the strongest responses were usually observed with Stem Span. Native leukemia blasts were also cultured in the presence of various single cytokines or cytokine combinations. The highest proliferation was usually observed in the presence of Flt3-Ligand (Flt3-L) when single cytokines were examined, and these responses could be further increased especially by combining Flt3-L with interleukin 3 (IL3), IL7 or stem cell factor (SCF). Proliferation could also be increased when ALL blasts were cultured in the presence of two commercially available fibroblast cell lines (Hs27 and HFL1). Based on these results we suggest that in vitro culture conditions for native human ALL blasts can be standardized by using serum-free culture media supplemented with exogenous Flt3-L+IL3+SCF, and the use of accessory cells can also be standardized by using well-characterized fibroblast cell lines. Detectable ALL blast proliferation can then be observed for most patients. Our experimental model can thereby be used for in vitro evaluation of possible antileukemic treatment strategies, and it will then allow comparison of experimental results between different studies.Balasubramanyam K et al. (MAY 2003) The Journal of biological chemistry 278 21 19134--40Small molecule modulators of histone acetyltransferase p300.
Histone acetyltransferases (HATs) are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine residues of histones by the addition of acetyl groups from acetyl-CoA. Dysfunction of these enzymes is often associated with the manifestation of several diseases, predominantly cancer. Here we report that anacardic acid from cashew nut shell liquid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferase activities. Although it does not affect DNA transcription, HAT-dependent transcription from a chromatin template was strongly inhibited by anacardic acid. Furthermore, we describe the design and synthesis of an amide derivative N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide (CTPB) using anacardic acid as a synthon, which remarkably activates p300 HAT activity but not that of p300/CBP-associated factor. Although CTPB does not affect DNA transcription, it enhances the p300 HAT-dependent transcriptional activation from in vitro assembled chromatin template. However, it has no effect on histone deacetylase activity. These compounds would be useful as biological switching molecules for probing into the role of p300 in transcriptional studies and may also be useful as new chemical entities for the development of anticancer drugs.Tay SS et al. (MAR 2003) Journal of immunology (Baltimore, Md. : 1950) 170 6 3315--22IFN-gamma reverses the stop signal allowing migration of antigen-specific T cells into inflammatory sites.
In humans the majority of endothelial cells (EC) constitutively express MHC class II Ags. We know that in vitro ECs can activate CD45RO(+) B7-independent CD4(+) T cells to proliferate and produce IL-2. The in vivo correlate of this T cell response is not known, and here we have explored whether endothelial expression of MHC class II Ags affects the transendothelial migration of alloreactive CD4(+) CD45RO(+) B7-independent T cells. Alloreactive CD4(+) T cell clones and lines were generated against HLA-DR11, DR13, DR4, and DR1 MHC Ags, and their rates of migration across untreated EC line Eahy.926 (MHC class II negative) or Eahy.926 transfected with CIITA (EahyCIITA) to express DR11 and DR13 were investigated. The migrations of EahyCIITA-specific T cell clones and lines were retarded in a DR-specific manner, and retardation was reversed in the presence of mAb to DR Ag. When investigating the ability of T cells to proliferate in response to EahyCIITA before and after transmigration, migrated cells were still able to proliferate, but the frequency of EahyCIITA-specific cells was much reduced compared with that of nonmigrated cells. The use of fluorescently labeled T cells revealed that specific cells become trapped within the endothelial monolayer. Pretreatment of EahyCIITA with IFN-gamma restored the ability of DR11- or DR13-specific T cells to transmigrate and proliferate, thus abrogating DR-specific retardation. We conclude that cognate interaction between T cells and endothelial MHC class II initiates a stop signal possibly similar to an immunological synapse, but this is overcome in an inflammatory milieu.Catalog #: Product Name: 15022 RosetteSepâ„¢ Human CD4+ T Cell Enrichment Cocktail Catalog #: 15022 Product Name: RosetteSepâ„¢ Human CD4+ T Cell Enrichment Cocktail Murdoch B et al. (MAR 2003) Proceedings of the National Academy of Sciences of the United States of America 100 6 3422--7Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo.
Human hematopoietic stem cells are defined by their ability to repopulate multiple hematopoietic lineages in the bone marrow of transplanted recipients and therefore are functionally distinct from hematopoietic progenitors detected in vitro. Although factors capable of regulating progenitors are well established, in vivo regulators of hematopoietic repopulating function are unknown. By using a member of the vertebrate Wnt family, Wnt-5A, the proliferation and differentiation of progenitors cocultured on stromal cells transduced with Wnt-5A or treated with Wnt-5A conditioned medium (CM) was unaffected. However, i.p. injection of Wnt-5A CM into mice engrafted with human repopulating cells increased multilineage reconstitution by textgreater3-fold compared with controls. Furthermore, in vivo treatment of human repopulating cells with Wnt-5A CM produced a greater proportion of phenotypically primitive hematopoietic progeny that could be isolated and shown to possess enhanced progenitor function independent of continued Wnt-5A treatment. Our study demonstrates that Wnt-5A augments primitive hematopoietic development in vivo and represents an in vivo regulator of hematopoietic stem cell function in the human. Based on these findings, we suggest a potential role for activation of Wnt signaling in managing patients exhibiting poor hematopoietic recovery shortly after stem cell transplantation. View PublicationCatalog #: Product Name: 05100 MyeloCultâ„¢ H5100 Catalog #: 05100 Product Name: MyeloCultâ„¢ H5100 Kohler JJ et al. (MAR 2003) Journal of leukocyte biology 73 3 407--16Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD4+ cells of lymphocyte or monocyte/macrophage lineages.
Human immunodeficiency virus type 1 (HIV-1) impacts the activation state of multiple lineages of hematopoietic cells. Chronic HIV-1 infection among individuals with progressive disease can be associated with increased levels of activated signal transducers and activators of transcription (STATs) in peripheral blood mononuclear cells. To investigate interactions between HIV-1 and CD4(+) cells, activated, phosphorylated STAT proteins in nuclear extracts from lymphocytic and promonocytic cell lines as well as primary monocyte-derived macrophages were measured. Levels of activated STATs increased six- to tenfold in HUT78 and U937 cells within 2 h following exposure to virions. The response to virus was dose-dependent, but kinetics of activation was delayed relative to interleukin-2 or interferon-gamma. Activation of STAT1, STAT3, and STAT5 occurred with diverse viral envelope proteins, independent of coreceptor use or viral replication. Envelope-deficient virions had no effect on STAT activation. Monoclonal antibody engagement of CD4 identified a novel role for CD4 as a mediator in the activation of multiple STATs. Results provide a model for HIV-1 pathogenesis in infected and noninfected hematopoietic cells.Catalog #: Product Name: 15028 RosetteSepâ„¢ Human Monocyte Enrichment Cocktail Catalog #: 15028 Product Name: RosetteSepâ„¢ Human Monocyte Enrichment Cocktail Cilliers T et al. (APR 2003) Journal of virology 77 7 4449--56The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
Human immunodeficiency virus type 1 (HIV-1) subtype C viruses with different coreceptor usage profiles were isolated from 29 South African patients with advanced AIDS. All 24 R5 isolates were inhibited by the CCR5-specific agents, PRO 140 and RANTES, while the two X4 viruses and the three R5X4 viruses were sensitive to the CXCR4-specific inhibitor, AMD3100. The five X4 or R5X4 viruses were all able to replicate in peripheral blood mononuclear cells that did not express CCR5. When tested using coreceptor-transfected cell lines, one R5 virus was also able to use CXCR6, and another R5X4 virus could use CCR3, BOB/GPR15, and CXCR6. The R5X4 and X4 viruses contained more-diverse V3 loop sequences, with a higher overall positive charge, than the R5 viruses. Hence, some HIV-1 subtype C viruses are able to use CCR5, CXCR4, or both CXCR4 and CCR5 for entry, and they are sensitive to specific inhibitors of entry via these coreceptors. These observations are relevant to understanding the rapid spread of HIV-1 subtype C in the developing world and to the design of intervention and treatment strategies. View PublicationCatalog #: Product Name: 15023 RosetteSepâ„¢ Human CD8+ T Cell Enrichment Cocktail 15623 RosetteSepâ„¢ Human CD8 Depletion Cocktail Catalog #: 15023 Product Name: RosetteSepâ„¢ Human CD8+ T Cell Enrichment Cocktail Catalog #: 15623 Product Name: RosetteSepâ„¢ Human CD8 Depletion Cocktail Yasui K et al. (JAN 2003) Stem cells (Dayton, Ohio) 21 2 143--51Differences between peripheral blood and cord blood in the kinetics of lineage-restricted hematopoietic cells: implications for delayed platelet recovery following cord blood transplantation.
Cord blood (CB) cells are a useful source of hematopoietic cells for transplantation. The hematopoietic activities of CB cells are different from those of bone marrow and peripheral blood (PB) cells. Platelet recovery is significantly slower after transplantation with CB cells than with cells from other sources. However, the cellular mechanisms underlying these differences have not been elucidated. We compared the surface marker expression profiles of PB and CB hematopoietic cells. We focused on two surface markers of hematopoietic cell immaturity, i.e., CD34 and AC133. In addition to differences in surface marker expression, the PB and CB cells showed nonidentical differentiation pathways from AC133(+)CD34(+) (immature) hematopoietic cells to terminally differentiated cells. The majority of the AC133(+)CD34(+) PB cells initially lost AC133 expression and eventually became AC133(-)CD34(-) cells. In contrast, the AC133(+)CD34(+) CB cells did not go through the intermediate AC133(-)CD34(+) stage and lost both markers simultaneously. Meanwhile, the vast majority of megakaryocyte progenitors were of the AC133(-)CD34(+) phenotype. We conclude that the delayed recovery of platelets after CB transplantation is due to both subpopulation distribution and the process of differentiation from AC133(+)CD34(+) cells. View PublicationCatalog #: Product Name: 04970 MegaCultâ„¢-C Complete Kit Without Cytokines 04971 MegaCultâ„¢-C Complete Kit with Cytokines 04064 Starter Kit for MethoCultâ„¢ H4034 Optimum 04900 MegaCultâ„¢-C Medium Without Cytokines 04901 MegaCultâ„¢-C Medium with Cytokines 04960 MegaCultâ„¢-C Collagen and Medium Without Cytokines 04961 MegaCultâ„¢-C Collagen and Medium with Cytokines Catalog #: 04970 Product Name: MegaCultâ„¢-C Complete Kit Without Cytokines Catalog #: 04971 Product Name: MegaCultâ„¢-C Complete Kit with Cytokines Catalog #: 04064 Product Name: Starter Kit for MethoCultâ„¢ H4034 Optimum Catalog #: 04900 Product Name: MegaCultâ„¢-C Medium Without Cytokines Catalog #: 04901 Product Name: MegaCultâ„¢-C Medium with Cytokines Catalog #: 04960 Product Name: MegaCultâ„¢-C Collagen and Medium Without Cytokines Catalog #: 04961 Product Name: MegaCultâ„¢-C Collagen and Medium with Cytokines Lin H et al. (JAN 2003) Stem cells (Dayton, Ohio) 21 2 152--61Multilineage potential of homozygous stem cells derived from metaphase II oocytes.
Human stem cells derived from human fertilized oocytes, fetal primordial germ cells, umbilical cord blood, and adult tissues provide potential cell-based therapies for repair of degenerating or damaged tissues. However, the diversity of major histocompatibility complex (MHC) antigens in the general population and the resultant risk of immune-mediated rejection complicates the allogenic use of established stem cells. We assessed an alternative approach, employing chemical activation of nonfertilized metaphase II oocytes for producing stem cells homozygous for MHC. By using F1 hybrid mice (H-2-B/D), we established stem cell lines homozygous for H-2-B and H-2-D, respectively. The undifferentiated cells retained a normal karyotype, expressed stage-specific embryonic antigen-1 and Oct4, and were positive for alkaline phosphatase and telomerase. Teratomatous growth of these cells displayed the development of a variety of tissue types encompassing all three germ layers. In addition, these cells demonstrated the potential for in vitro differentiation into endoderm, neuronal, and hematopoietic lineages. We also evaluated this homozygous stem cell approach in human tissue. Five unfertilized blastocysts were derived from a total of 25 human oocytes, and cells from one of the five hatched blastocysts proliferated and survived beyond two passages. Our studies demonstrate a plausible homozygous stem cell" approach for deriving pluripotent stem cells that can overcome the immune-mediated rejection response common in allotransplantation�Catalog #: Product Name: 03434 MethoCult™ GF M3434 Catalog #: 03434 Product Name: MethoCult™ GF M3434 Eichler H et al. (JAN 2003) Stem cells (Dayton, Ohio) 21 2 208--16Engraftment capacity of umbilical cord blood cells processed by either whole blood preparation or filtration.
Umbilical cord blood (UCB) preparation needs to be optimized in order to develop more simplified procedures for volume reduction, as well as to reduce the amount of contaminating cells within the final stem cell transplant. We evaluated a novel filter device (StemQuick((TM))E) and compared it with our routine buffy coat (BC) preparation procedure for the enrichment of hematopoietic progenitor cells (HPCs). Two groups of single or pooled UCB units were filtered (each n = 6), or equally divided in two halves and processed by filtration and BC preparation in parallel (n = 10). The engraftment capacity of UCB samples processed by whole blood (WB) preparation was compared with paired samples processed by filtration in the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse animal model. Filtration of UCB units in the two groups with a mean volume of 87.8 and 120.7 ml, respectively, and nucleated cell (NC) content of 9.7 and 23.8 x 10(8) resulted in a sufficient mean cell recovery for mononucleated cells ([MNCs] 74.2%-77.5%), CD34(+) cells (76.3%-79.0%), and colony-forming cells (64.1%-86.3%). Moreover, we detected a relevant depletion of the transplants for RBCs (89.2%-90.0%) and platelets ([PLTs] 77.5%-86.1%). In contrast, the mean depletion rate using BC processing proved to be significantly different for PLTs (10%, p = 0.03) and RBCs (39.6%, p textless 0.01). The NC composition showed a highly significant increase in MNCs and a decrease in granulocytes after filtration (p textless 0.01), compared with a less significant MNC increase in the BC group (p textless 0.05). For mice transplanted with WB-derived progenitors, we observed a mean of 15.3% +/- 15.5% of human CD45(+) cells within the BM compared with 19.9% +/- 16.8% for mice transplanted with filter samples (p = 0.03). The mean percentage of human CD34(+) cells was 4.2% +/- 3.1% for WB samples and 4.5% +/- 3.2% for filter samples (p = 0.68). As the data of NOD/SCID mice transplantation demonstrated a significant engraftment capacity of HPCs processed by filtration, no negative effect on the engraftment potential of filtered UCB cells versus non-volume-reduced cells from WB transplants was found. The StemQuick((TM))E filter devices proved to be a useful tool for Good Manufacturing Practices conform enrichment of HPCs and MNCs out of UCB. Filtration enables a quick and standardized preparation of a volume-reduced UCB transplant, including a partial depletion of granulocytes, RBCs, and PLTs without the need for centrifugation. Therefore, it seems very probable that filter-processed UCB transplants will also result in sufficient hematopoietic reconstitution in humans.Catalog #: Product Name: 04434 MethoCultâ„¢ H4434 Classic 04535 MethoCultâ„¢ H4535 Enriched Without EPO 04035 MethoCultâ„¢ H4035 Optimum Without EPO 04034 MethoCultâ„¢ H4034 Optimum 04435 MethoCultâ„¢ H4435 Enriched 04534 MethoCultâ„¢ H4534 Classic Without EPO 04564 Starter Kit for MethoCultâ„¢ H4534 Classic Without EPO Catalog #: 04434 Product Name: MethoCultâ„¢ H4434 Classic Catalog #: 04535 Product Name: MethoCultâ„¢ H4535 Enriched Without EPO Catalog #: 04035 Product Name: MethoCultâ„¢ H4035 Optimum Without EPO Catalog #: 04034 Product Name: MethoCultâ„¢ H4034 Optimum Catalog #: 04435 Product Name: MethoCultâ„¢ H4435 Enriched Catalog #: 04534 Product Name: MethoCultâ„¢ H4534 Classic Without EPO Catalog #: 04564 Product Name: Starter Kit for MethoCultâ„¢ H4534 Classic Without EPO Items 241 to 252 of 7892 total
Shop ByFilter Results- Resource Type
-
- Reference 7892 items
- Product Type
-
- 24 items
- Area of Interest
-
- 11 items
- Angiogenic Cell Research 48 items
- Cancer 600 items
- Cell Line Development 137 items
- Chimerism 5 items
- Cord Blood Banking 23 items
- Drug Discovery and Toxicity Testing 176 items
- Endothelial Cell Biology 2 items
- Epithelial Cell Biology 156 items
- HIV 51 items
- HLA 7 items
- Immunology 733 items
- Infectious Diseases 1 item
- Neuroscience 486 items
- Stem Cell Biology 2484 items
- Transplantation Research 53 items
- Brand
-
- 0 11 items
- ALDECOUNT 7 items
- ALDEFLUOR 216 items
- AggreWell 55 items
- ArciTect 1 item
- BrainPhys 45 items
- ClonaCell 83 items
- CryoStor 65 items
- ES-Cult 74 items
- EasyPick 1 item
- EasySep 750 items
- EpiCult 12 items
- HepatiCult 1 item
- ImmunoCult 7 items
- IntestiCult 142 items
- Lymphoprep 9 items
- MammoCult 45 items
- MegaCult 33 items
- MesenCult 133 items
- MethoCult 440 items
- MyeloCult 61 items
- MyoCult 2 items
- NeuroCult 350 items
- NeuroFluor 1 item
- PancreaCult 3 items
- PneumaCult 77 items
- RSeT 6 items
- ReLeSR 1 item
- RoboSep 20 items
- RosetteSep 252 items
- STEMdiff 47 items
- STEMvision 3 items
- SepMate 29 items
- StemSpan 219 items
- TeSR 1447 items
- mFreSR 3 items
- Cell and Tissue Source
-
- 24 items
- Cell Line
-
- 24 items
- Cell Type
-
- 12 items
- Airway Cells 40 items
- B Cells 134 items
- Brain Tumor Stem Cells 81 items
- Cancer Cells and Cell Lines 116 items
- Cardiomyocytes, PSC-Derived 8 items
- Dendritic Cells 59 items
- Dermal Cells 1 item
- Endothelial Cells 1 item
- Epithelial Cells 48 items
- Granulocytes and Subsets 61 items
- Hematopoietic Stem and Progenitor Cells 765 items
- Hepatic Cells 2 items
- Hybridomas 73 items
- Innate Lymphoid Cells 3 items
- Intestinal Cells 12 items
- Leukemia/Lymphoma Cells 8 items
- Mammary Cells 68 items
- Mesenchymal Stem and Progenitor Cells 132 items
- Monocytes 105 items
- Mononuclear Cells 32 items
- Myeloid Cells 99 items
- NK Cells 79 items
- Neural Cells, PSC-Derived 17 items
- Neural Stem and Progenitor Cells 376 items
- Neurons 134 items
- Plasma 3 items
- Pluripotent Stem Cells 1676 items
- Prostate Cells 7 items
- Renal Cells 2 items
- T Cells 178 items
- T Cells, CD4+ 84 items
- T Cells, CD8+ 48 items
- T Cells, Regulatory 18 items
Loading...Copyright © 2025 º£½ÇÆÆ½â°æ. All rights reserved.